Many deceased by neurologic criteria donors are administered inhalational agents during organ recovery surgery-a process that is characterised by warm and cold ischaemia followed by warm reperfusion. In certain settings, volatile anaesthetics (VA) are known to precondition organs to protect them from subsequent ischaemia-reperfusion injury. As such, we hypothesised that exposure to VA during organ procurement would improve post-graft survival. Lifebanc (organ procurement organisation [OPO] for NE Ohio) provided the investigators with a list of death by neurologic criteria organ donors cared for at three large tertiary hospitals in Cleveland between 2006 and 2016-details about the surgical recovery phase were extracted from the organ donors' medical records. De-identified data on graft survival were obtained from the United Network for Organ Sharing (UNOS). The collated data underwent comparative analysis based on whether or not VA were administered during procurement surgery. Records from 213 donors were obtained for analysis with 138 exposed and 75 not exposed. Demographics, medical histories, and organ procurement rates were similar between the two cohorts. For the primary endpoint, there were no significant differences observed in either early (30-day) or late (five-year) graft survival rates for kidney, liver, lung, or heart transplants. Our findings from this retrospective review of a relatively small cohort do not support the hypothesis that the use of VA during the surgical procurement phase improves graft survival. Reviews of larger datasets and/or a prospective study may be required to provide a definitive answer.
-a depressing outcome for individuals whose own organs have already failed and who have endured months to years of uncertainty after being listed on a transplant registry. The factors associated with graft failure can be divided into two categories: 1) intractable (donor status), and 2) modifiable. For the latter, the one modifiable factor for the organ procurement organisation (OPO) care team is donor management. Ensuring optimal care to correct brain death (BD)-induced systemic pathologies can help to increase the number of organs suitable for transplant 9, 10 .
There are validated intensive care unit (ICU) guidelines to manage the death by neurological criteria (DNC) donor and various trials of targeted care have recorded increases in organ availability [11] [12] [13] . Despite these positive steps there remain glaring deficiencies in donor care most notably during the organ surgical procurement phase-the component of the transplant cycle where involvement of anaesthesia professionals could be of significant benefit.
Notwithstanding the myriad of donor support strategies published by national and regional OPOs, it may come as a surprise to some readers that little effort has been expended to study, let alone attempt to optimise, the drug regimens employed during the surgical extraction phase 14 .
At the same time, findings from a wide variety of clinical settings have demonstrated the benefits of exposure to volatile anaesthetics ([VA] viz. isoflurane and sevoflurane) in advance of a manipulation or pathophysiologic insult that produces an acute reduction in oxygen availability 15 . VA preconditioning has been demonstrated to protect the commonly transplanted organs from ischaemia-reperfusion injury, including that caused by acute haemorrhage (note: exsanguination is a key component of the extraction surgery). Donor organs undergo substantial periods of ischaemia. Decreases in oxygen availability are believed to be significant contributors to both acute post-graft failure and unsuitability of an organ for transplant. Despite welldocumented VA-mediated cellular protection in a variety of clinical settings, the use of such agents is neither required nor standardised in the setting of organ procurement.
As a first step in assessing the utility of halogenated agents in transplantation, we tested the hypothesis that utilisation of VA during the organ procurement phase would positively impact graft function post-transplantation. We anticipated that a positive finding from our retrospective outcome analysis would support the use of inhalational anaesthesia as a ready mechanism to improve the quality and viability of organs available for transplant.
Materials and methods

Study population
The study protocol (#16-192) was approved by the Institutional Review Board of the Cleveland Clinic and the requirement for written informed consent was waived by the Institutional Review Board. The study was also approved by the Medical Advisory Board and Board of Directors of Lifebanc, the North East Ohio OPO. We conducted a tenyear retrospective assessment of graft outcomes for organs procured from DNC donors 18 years and older, cared for at Cleveland's major tertiary care centres (MetroHealth Hospital, University Hospitals-Cleveland Medical Center, and the Cleveland Clinic). Results from individuals who donated organs after circulatory determination of death were excluded from the review. All donor care was overseen by Lifebanc with standardised protocols guiding donor management employed across the three sites. As is common practice, the decision to administer VA during the procurement phase was made on a case-by-case basis by the anaesthesiologist member of the organ recovery team. Volatile anaesthesia was not provided in an ischaemic preconditioning regimen. It was administered continuously during the surgical recovery period until cross-clamping.
Record retrieval
This study used data from the Organ Procurement and Transplantation Network (OPTN). The data system includes data on all donors, wait-listed candidates, and transplant recipients in the US, submitted by the members of the OPTN. The Health Resources and Services Administration, US Department of Health and Human Services provides oversight to the activities of the OPTN contractor. Lifebanc generated the list of DNC donors with United Network for Organ Sharing (UNOS) identification numbers cared for between 2006 and 2016. The Lifebanc data included donor demographic details and the number and type of organs procured. A CONSORT diagram depicting this process is presented in Figure 1 . The research team subsequently obtained the intraoperative hospital records for these American Society of Anesthesiologists (ASA) Class VI subjects and subdivided the group based on the use of VA during procurement. Requests were then sent to UNOS for de-identified graft outcome information from the Standard Transplant Analysis and Research files database (current as of 9 September 2016) for the recipients of organs from VA and non-VA exposed donors. A research team member unaware of the treatment group assignments conducted the data extraction, and matched and collated the donor and recipient data for comparative analysis.
Data analysis
The obtained data were supplied by UNOS as the contractor for the OPTN. Our interpretation and reporting of these data in no way should be seen as an official policy of, or interpretation by the OPTN or the US Government. The primary outcome measure for this study was disparity in graft survival for organs obtained from VA and non-VA exposed donors. Graft survival was defined as the time between the most recent specific organ transplant and the failure of the graft. Graft outcome was censored at the event of all-cause graft failure, patient's death or study completion date (whichever occurred first). Based on anecdotal data, we assumed the group distributions to be ~2 :1 (66% in the VA group and 34% in the non-VA group). Based on that 2:1 ratio, to achieve 80% power with the use of a two-sided log-rank test at an overall significance level of 0.05, at least 213 graft survival records needed to be assessed.
The graft survival rates are depicted graphically using Kaplan-Meier curves and differences were tested for using log-rank test and Cox proportional hazard modelling. Secondary analyses focused on identifying differences (if any) between the two groups of donors with respect to demographics, organs procured, intraoperative management, and causes of acute graft failure. For quantitative variables, the t-test and Wilcoxon-Mann-Whitney test were used, and for qualitative variables the chi-square and Fisher's exact tests were used. Since missing information regarding graft survival was assumed to be randomly distributed between groups, no imputation was done for the analyses. All data were analysed with R statistical software, version 3.3.3 (https://www.r-project.org/), and conducted by a team member unaware of the treatment groups. Statistically significant differences were assumed when P <0.05.
Results
Records from 235 donors were obtained for analysis ( Figure  1 ). Twenty-two subjects were later excluded due to missing data (seven), young age (11), or wrong donor status (four donation after cardiac death criteria). The resultant cohort consisted of 138 DNC donors (64.7%) who received VA during the surgical recovery phase and 75 DNC donors (35.3%) who did not receive any type of anaesthetic agent. As no intravenous anaesthesia was employed for any of the donors, all general anaesthesias involved the use of VA. The reviewed charts did not contain explanations for the choice to use or withhold the administration of inhalational agents. The 2:1 ratio of general anaesthesias to non-general anaesthesias by and large held throughout the 10-year sampling period (Figure 2 ). Regarding the type of VA, 76 donors (55%) had received isoflurane and 59 (42.7%) sevoflurane; the three remaining subjects received desflurane. In addition to VA, an opioid was given to 28 donors (20.4%) in the VA group and 10 (13.3%) in the no-VA group (P=0.261).
General donor characteristics are presented in Table 1 with a more detailed breakdown provided in Supplemental  Table S1 (see AIC website). The two groups were similar with respect to age, physiologic characteristics, donor cause of death and graft cold ischaemia time. The only significant difference between groups in intraoperative measurements was mean systolic blood pressure, which was slightly lower in the VA group (P=0.044). Although there was no significant difference in overall categorical use of vasopressors (P=0.99), intervention for the no-VA group was typically limited to adrenaline (epinephrine) and noradrenaline (norepinephrine). In contrast, the use of dopamine, vasopressin, and phenylephrine was significantly more frequent in the VA donors (P <0.05). The median number of organs recovered was three for both groups (P=0.819) and there were no differences in the number of transplanted kidneys, livers, heart, or lungs when normalised for sample size. Kaplan-Meier curves detailing the short-(30-day) and long-term (five-year) graft survival rates for the four major transplanted organs are presented in Figure 3A -D. There were no significant differences between the VA and no-VA groups with respect to either short-or long-term graft survival of kidneys, livers, hearts, or lungs; all P values >0. 10 . In a secondary analysis comparing the two subgroups of isoflurane and sevoflurane versus the no-VA group, no statistically significant difference was seen ( Figure 4A-D) .
The most common cause of graft failure was chronic rejection (Table 2 ). Approximately half of the kidney, liver and heart graft failures were due to primary graft failure with no difference between groups (P >0.3). The other major negative outcome, recipient death, occurred with a functioning graft (additional details on graft survival rates and reasons for graft failure provided in Supplemental Table S2 ).
Confirming the absence of a VA effect, unadjusted hazard ratios for administering an inhalational agent were 0.7 (95% confidence intervals [CI] 0.86 to 2.38) for kidney, 1.33 (95% CI 0.36 to 1.54) for liver, 0.57 (95% CI 0.58 to 5.22) for heart, and 1.004 (95% CI 0.4 to 2.5) for lung. Adjustments for donor age, cold ischaemia time, opioid administration, and use of vasopressors did not alter these ratios substantially. The complete list of unadjusted and adjusted hazard ratios are presented in Supplemental Table S3 .
Discussion
To the best of our knowledge this is the first study to assess the impact of VA use during organ procurement on subsequent implanted graft survival. From a diverse donor pool we were unable to demonstrate any improved graft survival benefit from the administration of inhalational agents to DNC donors. This finding indicates that the decision to use VA during organ recovery procedures should not be based on a perceived benefit in terms of subsequent implanted graft survival. The concept that brief manipulation(s) could protect an organ or tissue from subsequent ischaemic injury was first put forward by Jennings et al. In their landmark 1986 paper 16 , Jennings' group reported on protective results in dogs that underwent four bouts of brief occlusion of the circumflex artery (five minutes) prior to a sustained period of ischaemia (40 minutes). In the ensuing 30 years, ischaemic preconditioning has been shown in preclinical studies to protect all of the commonly transplanted organs from a myriad of pathophysiologic insults (albeit not in a transplant setting). The translation of this phenomenon into clinical practice has not been smooth 17 but under controlled scenarios where there is a high probability of an ischaemic event various human preconditioning trials have demonstrated benefit with respect to improved organ function and reduced morbidity and mortality 18, 19 . Practical constraints on physically reducing bloodflow (access, duration of occlusion, etc.) have led to the search for pharmacologic alternatives-and one of the first recognised drug categories to provide cell protection was the VA 20 . VA, specifically defined as halogenated compounds such as isoflurane and sevoflurane, have been shown to directly precondition or indirectly enhance ischaemic preconditioning of a variety of different organs 21 . In a key example that modelled Jennings et al's study, Kersten and colleagues used a canine protocol which demonstrated that isoflurane (1 MAC [minimum alveolar concentration] for 65 minutes) prior to 60 minutes of coronary artery occlusion produced an equivalent reduction in infarct size as ischaemic preconditioning 22 . Additional positive preclinical reports soon followed 23, 24 . Anaesthetic preconditioning has now been well documented to also occur in humans [25] [26] [27] . Importantly, the cellular and metabolic changes that are integral to ischaemic preconditioning occur within minutes of exposure to an inhalational anaesthetic agent and can persist for hours; this suggested a potential benefit in the setting of surgical organ procurement from DNC donors. Yet despite this promising history we did not observe a beneficial effect of donor VA administration on subsequent implanted graft survival. The period during and immediately following BD is characterised by physiologic instability, the result first of intense sympathetic stimulation and significant release of catecholamines (the Cushing response) with transient vasoconstriction, hypertension, and tachycardia followed by the complete loss of sympathetic activity leading to hypotension and profound reductions in systemic vascular resistance 28 . Both conditions impair organ blood flow and induce tissue ischaemia. Organ function is further impaired by up-regulation of inflammatory mediators and adhesion molecules, and infiltration of circulating leukocytes 29 . Once BD is confirmed, care of the donor switches from restorative to supportive 30 where to some extent the acidosis and systemic effects of BD can be controlled by adjusting ventilation rates and/or by administration of vasoactive agents. It is during this period prior to surgical recovery that active interventions may be of benefit. Whether such pre-surgical intercessions should include VA remains to be determined.
Providing analgesia and inducing unconsciousness to deceased organ donors are unnecessary interventions per some authors 31 , but anaesthesiologists may view such declarative statements as antithetical with professional guidelines, which exhort them to strive to care for each patient's physical and psychological safety, comfort, and dignity. Thus some practitioners may be reluctant to provide muscle relaxants to a DNC donor in the absence of some form of pain control 32 . In this regard there may be merit in the suggestion that the term 'general anaesthesia' not be applied in the setting of administering VA (or intravenous agents) to deceased organ donors to decrease confusion . It is also important to note that VA can at times be useful adjuvants for controlling the reflex tachycardia and hypertension that can occur during the donation operation (even as some authors contest this application 34 ). While we did not see benefit from VA use we did find significant increased need for vasopressors to maintain blood pressure, but without identifying any harm from this practice.
The weaknesses of our study that need to be recognised are that: 1) it was a non-randomised retrospective review, 2) the use of VA was not controlled, nor were inhalational agents administered for the purpose of inducing ischaemic preconditioning, and 3) we lacked power to reliably confirm or exclude differences that could be clinically important, due to the relatively small sample size and the low rate of graft failures in both groups. However, the strength of our finding comes from having all subjects cared for by the same OPO employing a standardised set of protocols and care guidelines. As such, we conclude that VA use during the surgical recovery of organs from DNC donors does not appear to improve graft survival.
